Arash Salemi, MD,FACS

Clinical Chairman of Cardiothoracic Surgery, RWJBarnabas Health - Northern Region

Dr. Salemi performs all forms of adult cardiac surgery with a particular interest in valvular heart disease. An international leader in structural heart disease, he has been the principal investigator for numerous clinical trials and has served on the case review board for the Partner Trial for nearly a decade. He has individually performed more than 2,000 Transcatheter Aortic Valve Replacement (TAVR) procedures and has proctored physicians at over 50 centers across the world. He is developing techniques to enhance Transcatheter Mitral Valve Replacement and is a thought leader who sits on numerous cardiac surgical boards.

Dr. Salemi is an accomplished researcher, sits on the editorial boards of more the ten professional journals, and continues to push boundaries of clinical care standards for all areas of cardiac surgery. He will see patients at Newark Beth Israel Medical Center, Cooperman Barnabas Medical Center and Jersey City Medical Center.

Philosophy of Care

The care of the patient with cardiovascular disease is as much art as it is science. Each patient is unique. Risk factors and treatment options vary between individuals. With standards of care as a guide, a carefully constructed, individualized care pathway provides the best outcomes. Almost always, this entails strong collaborative and multidisciplinary evaluation and discussion. Having access to a wide range of therapeutic options allows us, as care providers, to customize the treatment plan. Our goal is to provide exemplary, state of the art, individualized care in a collaborative and compassionate patient environment.

Clinical Trials

• 2019: Abbott Tendyne CEASE MR Pivotal Study
• 2017: Edwards Early TAVR Clinical Trial
• 2016: PorticoTM Re-sheathable Transcatheter Aortic Valve System US IDE Trial (PORTICO)
• 2014: Cerebral Protection in Transcatheter Aortic Valve Replacement - The SENTINEL Study
• 2014: Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation (The COAPT Trial)